Ryan Maynard
Chief Financial Officer
San Francisco, California
About
Ryan Maynard serves as Chief Financial Officer at Cara Therapeutics since September 2022 and as a Member of the Board of Directors at Iovance Biotherapeutics since February 2015. With over 20 years of finance leadership experience within biopharmaceutical companies, he brings extensive expertise in corporate finance, investor relations, and strategic financial planning.
His career includes previous CFO roles at LetsGetChecked and Blade Therapeutics, demonstrating a consistent track record of financial leadership in the healthcare and biotech sectors. He started his career at Ernst & Young, LLP and holds a B.S. in Commerce–Accounting from Santa Clara University.
Professional Background
Cara Therapeutics (CFO)
As CFO since September 2022, Ryan oversees all financial operations, strategic planning, and investor relations for this biopharmaceutical company focused on developing new chemical entities designed to alleviate pruritus.
Iovance Biotherapeutics (Board Director)
Member of the Board of Directors since February 2015 at this pioneering company developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients. Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication.
LetsGetChecked (Former CFO)
Prior CFO role at the health technology company providing at-home health testing and telehealth services.
Blade Therapeutics (Former CFO)
Served as CFO at this clinical-stage biopharmaceutical company developing treatments for fibrotic diseases.
Areas of Expertise
- Biopharmaceutical finance leadership
- Corporate finance and strategic planning
- Investor relations
- SEC reporting and compliance
- Capital markets and fundraising
- M&A transactions